• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A 23-Gene Classifier urine test for prostate cancer prognosis.

作者信息

Guo Jinan, Johnson Heather, Zhang Xuhui, Feng Xiaoyan, Zhang Heqiu, Simoulis Athanasios, Wu Alan Hb, Xia Taolin, Li Fei, Tan Wanlong, Johnson Allan, Dizeyi Nishtman, Abrahamsson Per-Anders, Kenner Lukas, Chen Lingwu, Zhong Wanmei, Xiao Kefeng, Persson Jenny L, Zou Chang

机构信息

Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen Urology Minimally Invasive Engineering Centre, Shenzhen, China.

Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Clinical Medical Research Centre, Shenzhen, China.

出版信息

Clin Transl Med. 2021 Mar;11(3):e340. doi: 10.1002/ctm2.340.

DOI:10.1002/ctm2.340
PMID:33784002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7919118/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/68b8de07379d/CTM2-11-e340-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/c57c09667192/CTM2-11-e340-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/a0623f794ca6/CTM2-11-e340-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/cb65dd11fc01/CTM2-11-e340-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/68b8de07379d/CTM2-11-e340-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/c57c09667192/CTM2-11-e340-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/a0623f794ca6/CTM2-11-e340-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/cb65dd11fc01/CTM2-11-e340-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29ec/7919118/68b8de07379d/CTM2-11-e340-g004.jpg

相似文献

1
A 23-Gene Classifier urine test for prostate cancer prognosis.用于前列腺癌预后评估的23基因分类尿液检测
Clin Transl Med. 2021 Mar;11(3):e340. doi: 10.1002/ctm2.340.
2
A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.尿液三基因检测 panel 提高了 PSA 检测前列腺癌的特异性。
Prostate. 2011 Dec;71(16):1736-45. doi: 10.1002/pros.21390. Epub 2011 Apr 25.
3
Urine biomarkers in prostate cancer.前列腺癌的尿液生物标志物。
Nat Rev Urol. 2010 Feb;7(2):101-9. doi: 10.1038/nrurol.2009.261. Epub 2010 Jan 12.
4
Detection of miRNAs in urine of prostate cancer patients.前列腺癌患者尿液中微小RNA的检测
Medicina (Kaunas). 2016;52(2):116-24. doi: 10.1016/j.medici.2016.02.007. Epub 2016 Mar 11.
5
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.前瞻性多中心研究 PCA3 和 TMPRSS2-ERG 基因融合作为前列腺癌的诊断和预后尿液生物标志物。
Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.
6
A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.一组用于利用尿液样本诊断前列腺癌的生物标志物。
Anticancer Res. 2018 Mar;38(3):1471-1477. doi: 10.21873/anticanres.12373.
7
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.尿生物标志物在前列腺癌、膀胱癌和肾癌中的蛋白质组学研究。
Nat Rev Urol. 2013 Apr;10(4):206-18. doi: 10.1038/nrurol.2013.24. Epub 2013 Feb 26.
8
Early detection of prostate cancer with emphasis on genetic markers.前列腺癌的早期检测，重点是遗传标志物。
Acta Oncol. 2011 Jun;50 Suppl 1:18-23. doi: 10.3109/0284186X.2010.529824.
9
Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.开发和验证一种 25 基因检测 panel 的尿液检测方法，用于前列腺癌的诊断和潜在的治疗随访。
BMC Med. 2020 Dec 1;18(1):376. doi: 10.1186/s12916-020-01834-0.
10
Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection.两种用于前列腺癌检测的线粒体DNA生物标志物的评估。
Cancer Biomark. 2015;15(6):763-73. doi: 10.3233/CBM-150518.

引用本文的文献

1
A non-invasive 25-Gene PLNM-Score urine test for detection of prostate cancer pelvic lymph node metastasis.一种用于检测前列腺癌盆腔淋巴结转移的非侵入性25基因PLNM评分尿液检测。
Prostate Cancer Prostatic Dis. 2025 Mar;28(1):94-102. doi: 10.1038/s41391-023-00758-z. Epub 2024 Feb 2.
2
K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer.基于K-RAS相关基因突变的算法预测乳腺癌亚型尤其是三阴性乳腺癌患者的治疗反应
Cancers (Basel). 2022 Oct 28;14(21):5322. doi: 10.3390/cancers14215322.
3
Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients.

本文引用的文献

1
Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.开发和验证一种 25 基因检测 panel 的尿液检测方法，用于前列腺癌的诊断和潜在的治疗随访。
BMC Med. 2020 Dec 1;18(1):376. doi: 10.1186/s12916-020-01834-0.
2
A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.一组用于利用尿液样本诊断前列腺癌的生物标志物。
Anticancer Res. 2018 Mar;38(3):1471-1477. doi: 10.21873/anticanres.12373.
3
A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
基于基因突变的算法预测结直肠癌患者的治疗反应
Cancers (Basel). 2022 Apr 18;14(8):2045. doi: 10.3390/cancers14082045.
4
Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients.新诊断前列腺癌患者临床意义分子分类的非侵入性尿液检测
Front Med (Lausanne). 2021 Sep 14;8:721554. doi: 10.3389/fmed.2021.721554. eCollection 2021.
基于活检的 17 基因基因组前列腺评分作为预测临床局限性疾病手术治疗男性转移和前列腺癌死亡的指标。
Eur Urol. 2018 Jan;73(1):129-138. doi: 10.1016/j.eururo.2017.09.013. Epub 2017 Oct 6.
4
Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.细胞游离尿液中用于前列腺癌的诊断和预后的 microRNA 生物标志物。
Eur Urol Focus. 2018 Dec;4(6):825-833. doi: 10.1016/j.euf.2017.02.018. Epub 2017 Mar 9.
5
Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.前列腺切除术后高危男性中Decipher基因组分类器预测转移性疾病发生性能的个体患者水平荟萃分析。
J Clin Oncol. 2017 Jun 20;35(18):1991-1998. doi: 10.1200/JCO.2016.70.2811. Epub 2017 Mar 30.
6
Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.基于血液和尿液的前列腺癌生物标志物：用于检测和治疗决策的新型生物标志物综述与比较
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19. doi: 10.1038/pcan.2016.59. Epub 2016 Dec 6.
7
Use of two gene panels for prostate cancer diagnosis and patient risk stratification.使用两个基因检测板进行前列腺癌诊断和患者风险分层。
Tumour Biol. 2016 Aug;37(8):10115-22. doi: 10.1007/s13277-015-4619-0. Epub 2016 Jan 28.
8
Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.基于前列腺切除术治疗的男性患者活检生成的细胞周期进展评分的预后价值。
J Urol. 2014 Aug;192(2):409-14. doi: 10.1016/j.juro.2014.02.003. Epub 2014 Feb 7.
9
Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.多机构验证 CAPRA-S 评分在预测根治性前列腺切除术后疾病复发和死亡中的作用。
Eur Urol. 2014 Jun;65(6):1171-7. doi: 10.1016/j.eururo.2013.03.058. Epub 2013 Apr 8.
10
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.预测前列腺癌根治术后10年复发概率的术前列线图。
J Natl Cancer Inst. 2006 May 17;98(10):715-7. doi: 10.1093/jnci/djj190.